Phage Displayed HBV Core Antigen with Immunogenic Activity

Bahadır, Aylin Özdemir; Balcıoğlu, Bertan Koray; Uzyol, Kamil Serkan; Hatipoğlu, İbrahim; Söğüt, İbrahim; Başalp, Aynur; Erdağ, Berrin

doi:10.1007/s12010-011-9365-1

Cited by 19 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transgenic mice expressing this HER2 variant that were vaccinated with this phage developed fewer tumors, the tumors were smaller, and the latency period was extended likely as a result of overcoming the suppressive tumor microenvironment [ 110 ]. Collectively, these results and the results from many additional studies [ 111 , 112 , 113 , 114 , 115 ] indicate that phages might provide a reliable and cost-effective approach for both vaccine development and delivery.…”

Section: Genetically Engineered Phages For Eukaryotic Applicationsmentioning

confidence: 73%

The Many Applications of Engineered Bacteriophages—An Overview

2021

View full text Add to dashboard Cite

Since their independent discovery by Frederick Twort in 1915 and Felix d’Herelle in 1917, bacteriophages have captured the attention of scientists for more than a century. They are the most abundant organisms on the planet, often outnumbering their bacterial hosts by tenfold in a given environment, and they constitute a vast reservoir of unexplored genetic information. The increased prevalence of antibiotic resistant pathogens has renewed interest in the use of naturally obtained phages to combat bacterial infections, aka phage therapy. The development of tools to modify phages, genetically or chemically, combined with their structural flexibility, cargo capacity, ease of propagation, and overall safety in humans has opened the door to a myriad of applications. This review article will introduce readers to many of the varied and ingenious ways in which researchers are modifying phages to move them well beyond their innate ability to target and kill bacteria.

show abstract

Section: Genetically Engineered Phages For Eukaryotic Applicationsmentioning

confidence: 73%

The Many Applications of Engineered Bacteriophages—An Overview

2021

View full text Add to dashboard Cite

show abstract

“…Therefore, immunizations containing the entire antigen generate a more specific response against the target [38,39]. Recently, a full-length HBV core antigen (HBcAg) was displayed on the phage surface as a pIII fusion [40]. In addition, Ozdemir-Bahadir and colleagues successfully obtained anti-HBcAg monoclonal antibodies from BALB/c mice immunized with HBcAg-displaying phages.…”

Section: Discussionmentioning

confidence: 99%

Cost effective filamentous phage based immunization nanoparticles displaying a full-length hepatitis B virus surface antigen

Balcıoğlu¹,

Ozdemir-Bahadir²,

Hinc³

et al. 2014

ABB

Self Cite

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is one of the major causes of chronic hepatitis, cirrhosis and liver cancer. In combating HBV infections, HBV diagnosis and vaccination are therefore critical. The hepatitis B virus surface antigen (HBsAg) is a key target molecule in developing vaccines and diagnostic systems. To date, although HBsAg has been expressed in bacteria, yeasts and mammalian cells, there are still limitations in the existing ones, which leave the necessity for searching new HBsAg production methods. In this study, a simple phage display-based method was developed to produce the purified full-length HBsAg molecules for further immunization studies. For this purpose, the HBsAg coding gene was cloned into a pCANTAB5E phagemid vector and expressed on the surface of M13 filamentous phages. The HBsAg-expressing phage nanosystem was then used as immunization agent in BALB/cJ mice. The ELISA results for sera obtained from mice immunized with HBsAg-displaying phage particles revealed an immune response against HBsAg. These results demonstrate the potential use of a full-length antigen to be displayed on phages as cost effective adjuvant-free immunization agents as an alternative to the highly purified and more expensive antigens conjugated with carrier molecules.

show abstract

“…Phages offer the advantage of rapid and uniform replication, allowing for inexpensive and sustainable production on a large scale. Phages have been researched for vaccination against foot and mouth disease, 53 hepatitis B, 54 Epstein-Barr virus, 55 and numerous other infectious diseases. Some examples are highlighted in detail below.…”

Section: Phages As a Vaccination Platform Against Infectious Diseasesmentioning

confidence: 99%

Phage display as a tool for vaccine and immunotherapy development

Hess

Jewell

2019

Bioengineering & Transla Med

View full text Add to dashboard Cite

Bacteriophages, or phages, are viruses that specifically infect bacteria and coopt the cellular machinery to create more phage proteins, eventually resulting in the release of new phage particles. Phages are heavily utilized in bioengineering for applications ranging from tissue engineering scaffolds to immune signal delivery. Of specific interest to vaccines and immunotherapies, phages have demonstrated an ability to activate both the innate and adaptive immune systems. The genome of these viral particles can be harnessed for DNA vaccination, or the surface proteins can be exploited for antigen display. More specifically, genes that encode an antigen of interest can be spliced into the phage genome, allowing antigenic proteins or peptides to be displayed by fusion to phage capsid proteins. Phages therefore present antigens to immune cells in a highly ordered and repetitive manner. This review discusses the use of phage with adjuvanting activity as antigen delivery vehicles for vaccination against infectious disease and cancer. K E Y W O R D S bacteriophage, biomaterials, drug delivery, immunology, nanotechnology, phage display, vaccine 1 | INTRODUCTION Bacteriophages, or phages, are prokaryotic viruses that specifically infect bacteria, and are the most abundant life form on earth. 1 Phages were first discovered in the early 20th century and noted for their antibacterial activity. The practice of administering phages (i.e., phage therapy) to patients suffering from bacterial infections began shortly after their discovery, but was controversial largely due to lack of mechanistic knowledge and variable success rates. In fact, the treatment was largely abandoned upon the discovery of antibiotics. 2 Research in this field was reenergized, however, following the development of phage display systems in 1985. 3 George Smith, a chemist at the University of Missouri, demonstrated fusion of peptides to the outer (i.e., capsid) proteins of phages enabling surface display. This work, for which Smith shared a Nobel Prize in 2018, laid the ground work for affinity selection, epitope mapping, and antibody discovery. Since this time, phages have been an important tool for the bioengineering field, exploited for a range of applications including theranostics, 4 batteries, 5,6 drug delivery, 7 and vaccine development. 1Phages are one of many nanotechnologies being investigated for these applications. This review will focus on the advantages that phages provide to the nanomedicine field, specifically vaccination and immunotherapy. Nanomedicine ranges from diagnostics to treatments and relies on the fields of biomedical and chemical engineering,

show abstract

Phage Displayed HBV Core Antigen with Immunogenic Activity

Cited by 19 publications

References 34 publications

The Many Applications of Engineered Bacteriophages—An Overview

The Many Applications of Engineered Bacteriophages—An Overview

Cost effective filamentous phage based immunization nanoparticles displaying a full-length hepatitis B virus surface antigen

Phage display as a tool for vaccine and immunotherapy development

Contact Info

Product

Resources

About